| scholarly article | Q13442814 |
| P50 | author | Gabriela Chiosis | Q29515233 |
| Leandro Cerchietti | Q39201064 | ||
| Kojo Elenitoba-Johnson | Q62479915 | ||
| P2093 | author name string | Ari Melnick | |
| John P Leonard | |||
| Tony Taldone | |||
| Wayne Tam | |||
| Rita Shaknovich | |||
| Shao Ning Yang | |||
| Betty Chang | |||
| Rebecca L Goldstein | |||
| John Gerecitano | |||
| P2860 | cites work | Src-family kinases in B-cell development and signaling | Q24307580 |
| Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma | Q24613755 | ||
| STRING 8--a global view on proteins and their functional interactions in 630 organisms | Q24656073 | ||
| A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma | Q24680233 | ||
| Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray | Q28204313 | ||
| Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90 | Q28249103 | ||
| Translocation of the B cell antigen receptor into lipid rafts reveals a novel step in signaling | Q28513972 | ||
| A guided tour into subcellular colocalization analysis in light microscopy | Q29547199 | ||
| Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors | Q29547463 | ||
| Geldanamycin-induced Lyn dissociation from aberrant Hsp90-stabilized cytosolic complex is an early event in apoptotic mechanisms in B-chronic lymphocytic leukemia | Q30157536 | ||
| Regulation of the Src family kinase Lck by Hsp90 and ubiquitination | Q30164012 | ||
| High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells | Q30433183 | ||
| Displacement affinity chromatography of protein phosphatase one (PP1) complexes | Q33383636 | ||
| A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas | Q33588432 | ||
| The role of Hsp90N, a new member of the Hsp90 family, in signal transduction and neoplastic transformation | Q34105950 | ||
| SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma | Q36445884 | ||
| Cholesterol reporter molecules | Q36898794 | ||
| Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models | Q37208563 | ||
| Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies | Q37235682 | ||
| Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATP-competitive inhibitors | Q37661597 | ||
| Hsp90 is essential for the synthesis and subsequent membrane association, but not the maintenance, of the Src-kinase p56(lck). | Q38482173 | ||
| PU-H71 effectively induces degradation of IκB kinase β in the presence of TNF-α. | Q39082242 | ||
| SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas | Q39140068 | ||
| CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma | Q43864036 | ||
| Membrane cholesterol content accounts for developmental differences in surface B cell receptor compartmentalization and signaling | Q46477086 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 4559-4571 | |
| P577 | publication date | 2015-11-03 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma | |
| P478 | volume | 125 |
| Q38752029 | "Omics"-Informed Drug and Biomarker Discovery: Opportunities, Challenges and Future Perspectives |
| Q54425017 | Adapting to stress - chaperome networks in cancer. |
| Q58582458 | Chaperome heterogeneity and its implications for cancer study and treatment |
| Q36655158 | Chemical Tools to Investigate Mechanisms Associated with HSP90 and HSP70 in Disease |
| Q36596874 | Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas |
| Q47331796 | Drug-perturbation-based stratification of blood cancer |
| Q64087351 | Germinal center-derived lymphomas: The darkest side of humoral immunity |
| Q90111435 | HSP90 inhibitor PU-H71 increases radiosensitivity of breast cancer cells metastasized to visceral organs and alters the levels of inflammatory mediators |
| Q51173647 | HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment. |
| Q52593925 | How Biophysical Forces Regulate Human B Cell Lymphomas. |
| Q54990441 | Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen. |
| Q50942188 | Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma. |
| Q37691056 | Integrating Pharmacoproteomics into Early-Phase Clinical Development: State-of-the-Art, Challenges, and Recommendations |
| Q28076871 | Precision medicine: from pharmacogenomics to pharmacoproteomics |
| Q47678542 | Proteomic interrogation of HSP90 and insights for medical research |
| Q49888075 | Role of Bruton's tyrosine kinase in B cells and malignancies |
| Q40974570 | Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas |
| Q33587128 | Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma |
Search more.